Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Jeon, Da Som; Kim, Ho Cheol; Kim, Se Hee; Kim, Taejung; Kim, Hong Kwan; Moon, Mi Hyung; Beck, Kyongmin Sarah; Suh, Yong Jae; Song, Changhoon; Ahn, Jin Seok; Lee, Jeong Eun; Lim, Jeong Uk; Jeon, Jae Hyun; Jung, Kyu‐Won; Jung, Chi Young; Cho, Jeong Su; Choi, Yoo‐Duk; Hwang, Seung-Sik; Choi, Chang‐Min

doi:10.4143/crt.2022.264

Cited by 37 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, prior pulmonary TB remained independent factor associated with worse survival and confirmed our study result. For cancer subtype, small cell lung cancer, which was associated with higher mortality than non-small cell lung cancer, was similar as previous report ( 21 ). Under such high mortality in small cell lung cancer, the impact of prior TB might be masked and not significant.…”

Section: Discussionsupporting

confidence: 91%

Prior treated tuberculosis and mortality risk in lung cancer

Liao

Lee

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundLung cancer is one of the leading causes of cancer death worldwide, and tuberculosis (TB) is a common pre-existing disease. However, there is scarce literature studying the mortality risk in patients with prior TB and subsequent lung cancer.MethodsWe recruited lung cancer patients from the Taiwan Cancer Registry from 2011 to 2015 and classified them into two groups according to presence or absence of prior TB. We then matched them in a ratio of 1:4 using the exact matching approach. The mortality risk within 3 years after diagnosis of lung cancer was analyzed and compared between these two groups.ResultsDuring the study period, 43,472 patients with lung cancer were recruited, and of these, 1,211 (2.79%) patients had prior TB. After matching, this cohort included 5,935 patients with lung cancer in two groups: patients with prior TB before lung cancer (n = 1,187) and those without (n = 4,748). After controlling for demographic factors and comorbidities, the patients with prior TB had increased adjusted hazard ratios of 1.13 (95% CI: 1.04–1.23) and 1.11 (1.02–1.21) for all-cause and cancer-specific 3-year mortality, respectively, compared to the lung cancer patients without prior TB. Duration between TB and lung cancer (<1 year vs. 1–3 years vs. >3 years) had no differences for mortality risk.ConclusionIn the present study, 2.79% patients with lung cancer had prior TB, which was associated with higher 3-year mortality after they developed lung cancer. The mortality risk with prior TB did not decrease even if >3 years passed before diagnosis of lung cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Prior treated tuberculosis and mortality risk in lung cancer

Liao

Lee

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…This high mortality can be attributed to two main reasons: late diagnosis and the inefficiency of the treatments available. Most of the patients present an advanced stage of the disease at the time of diagnosis, leading to an expected survival at 2 of 17 5 years below 10% [2][3][4][5]. Novel reliable, sensitive, and accurate diagnostic tests are required since early-stage identification is associated with longer life expectancy.…”

Section: Introductionmentioning

confidence: 99%

Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection

D’Ambrosi

Giannoukakos

Antunes-Ferreira

et al. 2023

IJMS

View full text Add to dashboard Cite

Despite the diversity of liquid biopsy transcriptomic repertoire, numerous studies often exploit only a single RNA type signature for diagnostic biomarker potential. This frequently results in insufficient sensitivity and specificity necessary to reach diagnostic utility. Combinatorial biomarker approaches may offer a more reliable diagnosis. Here, we investigated the synergistic contributions of circRNA and mRNA signatures derived from blood platelets as biomarkers for lung cancer detection. We developed a comprehensive bioinformatics pipeline permitting an analysis of platelet-circRNA and mRNA derived from non-cancer individuals and lung cancer patients. An optimal selected signature is then used to generate the predictive classification model using machine learning algorithm. Using an individual signature of 21 circRNA and 28 mRNA, the predictive models reached an area under the curve (AUC) of 0.88 and 0.81, respectively. Importantly, combinatorial analysis including both types of RNAs resulted in an 8-target signature (6 mRNA and 2 circRNA), enhancing the differentiation of lung cancer from controls (AUC of 0.92). Additionally, we identified five biomarkers potentially specific for early-stage detection of lung cancer. Our proof-of-concept study presents the first multi-analyte-based approach for the analysis of platelets-derived biomarkers, providing a potential combinatorial diagnostic signature for lung cancer detection.

show abstract

“…Similar results have been reported also in research conducted in other geographical areas than ours. A study conducted by Da Som Jeon and colleagues on a South Korean cohort showed a better five-year survival for women with NSCLC, also stage-dependent [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

The Nine-Year Survival of Patients Operated for Non-Small-Cell Lung Carcinoma in a Tertiary Centre: The Impact of the Tumour Stage and Other Patient-Related Parameters

Vlăsceanu,

Mahler,

Marghescu

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: The mainstay treatment of non-small-cell lung carcinoma is still surgery, but its impact on survival beyond nine years has never been reported/analysed in Romania. Therefore, we studied the clinical characteristics and the short- and long-term survival of a population of 1369 patients diagnosed and treated in a single institution, with the variables included in the database being collected retrospectively. Materials and Methods: In this paper, we aimed to study a number of factors that might influence prognosis and survival in non-small bronchopulmonary carcinoma. Consequently, we analysed a series of parameters such as the age of patients, their sex, the histopathological type, the tumour stage, the presence of bronchial invasion, and the completeness of surgical resection. Results: All patients underwent major lung resection for curative purposes (pneumonectomy, lobectomy, or bilobectomy) between January 2015 and January 2023. The vital status of patients included in the study was obtained by checking the DGEP (General Directorate for Persons Record) database and verifying the reporting of “non-deceased” by the hospital administrative database, as well as by telephone interviews (with patients or their relatives). On univariate analysis, predictors of worse survival were the following: male sex (the hazard of death was 1.54 times higher in men); pT (compared to pT1 tumours, pT2 tumours have a 1.60 times higher hazard of death, pT3 tumours have a 2.16 times higher hazard, and pT4 tumours have a 2.97 times higher hazard); maximum tumour size (a 10 mm increase in tumour size is associated with a 10% increase in the hazard of death); the degree of differentiation (compared to patients with G1 tumours, those with G3 tumours have a 2.16 times higher hazard of death); resectability (compared to R0, R1 B+ has a 1.84 times higher hazard of death, R1 V+ has a 1.82 times higher hazard of death, and R1 B+&V+ has a 2.40 times higher hazard of death). Conclusions: As a result, long-term survival can be achieved after complete surgery for NSCLC, and factors that classically predict overall survival suggest that both the initial tumour aggressiveness and host characteristics act beyond the period usually considered in oncology.

show abstract

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

Cited by 37 publications

References 25 publications

Prior treated tuberculosis and mortality risk in lung cancer

Prior treated tuberculosis and mortality risk in lung cancer

Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection

The Nine-Year Survival of Patients Operated for Non-Small-Cell Lung Carcinoma in a Tertiary Centre: The Impact of the Tumour Stage and Other Patient-Related Parameters

Contact Info

Product

Resources

About